United Therapeutics Revenue 2006-2019 | UTHR

United Therapeutics revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
United Therapeutics Annual Revenue
(Millions of US $)
2018 $1,628
2017 $1,725
2016 $1,599
2015 $1,466
2014 $1,289
2013 $1,117
2012 $916
2011 $743
2010 $593
2009 $359
2008 $281
2007 $211
2006 $160
2005 $116
United Therapeutics Quarterly Revenue
(Millions of US $)
Q2 2019 $374
Q1 2019 $363
Q4 2018 $381
Q3 2018 $413
Q2 2018 $445
Q1 2018 $389
Q4 2017 $465
Q3 2017 $446
Q2 2017 $445
Q1 2017 $371
Q4 2016 $409
Q3 2016 $408
Q2 2016 $413
Q1 2016 $369
Q4 2015 $405
Q3 2015 $386
Q2 2015 $347
Q1 2015 $328
Q4 2014 $346
Q3 2014 $330
Q2 2014 $323
Q1 2014 $289
Q4 2013 $289
Q3 2013 $302
Q2 2013 $281
Q1 2013 $245
Q4 2012 $244
Q3 2012 $242
Q2 2012 $226
Q1 2012 $204
Q4 2011 $195
Q3 2011 $202
Q2 2011 $184
Q1 2011 $163
Q4 2010 $161
Q3 2010 $169
Q2 2010 $135
Q1 2010 $129
Q4 2009 $98
Q3 2009 $97
Q2 2009 $84
Q1 2009 $80
Q4 2008 $76
Q3 2008 $75
Q2 2008 $69
Q1 2008 $62
Q4 2007 $60
Q3 2007 $59
Q2 2007 $52
Q1 2007 $40
Q4 2006 $46
Q3 2006 $40
Q2 2006 $40
Q1 2006 $33
Q4 2005 $30
Q3 2005 $33
Q2 2005 $30
Q1 2005 $23
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $3.487B $1.628B
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. United Therapeutics (UT) has an overarching commitment to environmental sustainability. The company's product candidates include Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability in PAH patients. Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $59.064B 36.38
Takeda Pharmaceutical (TAK) Japan $26.341B 8.22
Astellas Pharma (ALPMY) Japan $26.215B 12.85
UCB SA (UCBJF) Belgium $15.008B 0.00
Grifols, S.A (GRFS) Spain $15.002B 19.14
Eisai (ESALY) Japan $14.332B 24.64
Merck (MKGAF) Germany $13.654B 18.63
Ionis Pharmaceuticals (IONS) United States $9.481B 20.45
Ono Pharmaceutical (OPHLF) Japan $9.383B 20.06
Neurocrine Biosciences (NBIX) United States $8.689B 0.00
IPSEN SA ADR (IPSEY) France $8.520B 0.00
Sage Therapeutics (SAGE) United States $8.318B 0.00
Catalent (CTLT) United States $8.054B 32.32
Jazz Pharmaceuticals (JAZZ) Ireland $7.439B 9.79
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.781B 0.00
STADA ARZNEIMI (STDAF) Germany $5.547B 0.00
Orion OYJ (ORINY) Finland $5.275B 27.16
Hypermarcas (HYPMY) Brazil $4.735B 17.02
FibroGen (FGEN) United States $3.750B 93.78
Tilray (TLRY) Canada $3.415B 0.00
Nektar Therapeutics (NKTR) United States $3.188B 0.00
Evotec AG (EVTCY) Germany $3.120B 42.71
Taro Pharmaceutical Industries (TARO) Israel $3.103B 11.12
Arrowhead Pharmaceuticals (ARWR) United States $2.767B 63.44
PTC Therapeutics (PTCT) United States $2.614B 0.00
Xencor (XNCR) United States $2.284B 49.79
Portola Pharmaceuticals (PTLA) United States $2.085B 0.00
Zogenix (ZGNX) United States $2.057B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.621B 59.00
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
USANA Health Sciences (USNA) United States $1.452B 14.56
Corcept Therapeutics (CORT) United States $1.439B 19.78
Ironwood Pharmaceuticals (IRWD) United States $1.404B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.384B 22.84
Heron Therapeutics (HRTX) United States $1.349B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.205B 0.00
Aerie Pharmaceuticals (AERI) United States $1.129B 0.00
Radius Health (RDUS) United States $1.040B 0.00
ArQule (ARQL) United States $1.039B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.837B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.718B 3.20
TherapeuticsMD (TXMD) United States $0.716B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.552B 0.00
Karyopharm Therapeutics (KPTI) United States $0.545B 0.00
Concordia (CXRXF) Canada $0.533B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.518B 0.00
Akebia Therapeutics (AKBA) United States $0.511B 0.00
Endo (ENDP) Ireland $0.505B 0.89
Aptorum Group (APM) China $0.477B 0.00
Indivior (INVVY) United States $0.466B 1.68
Crinetics Pharmaceuticals (CRNX) United States $0.437B 0.00
Dermira (DERM) United States $0.430B 0.00
Dova Pharmaceuticals (DOVA) United States $0.427B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.421B 19.12
ImmunoGen (IMGN) United States $0.412B 0.00
Siga Technologies (SIGA) United States $0.411B 0.96
Flexion Therapeutics (FLXN) United States $0.409B 0.00
Translate Bio (TBIO) United States $0.405B 0.00
ChemoCentryx (CCXI) United States $0.376B 0.00
Innate Pharma SA (IPHYF) France $0.374B 0.00
Collegium Pharmaceutical (COLL) United States $0.366B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.354B 0.00
Organogenesis Holdings (ORGO) United States $0.326B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.322B 0.00
CV Sciences (CVSI) United States $0.317B 0.00
Xeris Pharmaceuticals (XERS) United States $0.292B 0.00
Harpoon Therapeutics (HARP) United States $0.286B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.285B 0.00
CannTrust Holdings (CTST) Canada $0.280B 0.00
KalVista Pharmaceuticals (KALV) United States $0.280B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.256B 0.00
Lannett Co Inc (LCI) United States $0.255B 2.48
DURECT (DRRX) United States $0.250B 0.00
OptiNose (OPTN) United States $0.249B 0.00
Concert Pharmaceuticals (CNCE) United States $0.244B 0.00
Recro Pharma (REPH) United States $0.241B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.219B 0.00
Calithera Biosciences (CALA) United States $0.210B 0.00
Ocular Therapeutix (OCUL) United States $0.199B 0.00
Molecular Templates (MTEM) United States $0.186B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.176B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.176B 0.00
Taiwan Liposome (TLC) Taiwan $0.175B 0.00
Nature's Sunshine Products (NATR) United States $0.174B 29.03
Redhill Biopharma (RDHL) Israel $0.147B 0.00
IMV INC (IMV) Canada $0.140B 0.00
Ardelyx (ARDX) United States $0.135B 0.00
GlycoMimetics (GLYC) United States $0.132B 0.00
Jounce Therapeutics (JNCE) United States $0.130B 0.00
Generex Biotechnology (GNBT) United States $0.128B 0.00
Majesco Entertainment (PTE) United States $0.119B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.117B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.107B 0.00
MEI Pharma (MEIP) United States $0.106B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.104B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.098B 0.00
Iterum Therapeutics (ITRM) Ireland $0.094B 0.00
Mast Therapeutics (SVRA) United States $0.092B 0.00
Aquestive Therapeutics (AQST) United States $0.088B 0.00
Neos Therapeutics (NEOS) United States $0.088B 0.00
Cardiome Pharma (CORV) Canada $0.085B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.085B 32.41
Genocea Biosciences (GNCA) United States $0.082B 0.00
Natural Alternatives (NAII) United States $0.076B 7.62
RENEURON GP (RNUGF) United Kingdom $0.075B 0.00
MediWound (MDWD) Israel $0.074B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.074B 0.00
Nivalis Therapeutics (ALPN) United States $0.071B 0.00
Champions Oncology (CSBR) United States $0.069B 598.00
Infinity Pharmaceuticals (INFI) United States $0.068B 0.00
China SXT Pharmaceuticals (SXTC) China $0.068B 0.00
Otonomy (OTIC) United States $0.067B 0.00
Novan (NOVN) United States $0.065B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.063B 0.00
Pharmaxis (PXSLY) Australia $0.060B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.059B 0.00
SCYNEXIS (SCYX) United States $0.058B 0.00
Capnia (SLNO) United States $0.057B 0.00
Lipocine (LPCN) United States $0.053B 0.00
Medicure (MCUJF) Canada $0.053B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.053B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.046B 0.00
ElectroCore (ECOR) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.044B 0.00
CTI BioPharma (CTIC) United States $0.038B 0.00
Mannatechorporated (MTEX) United States $0.036B 0.00
Bio-Path Holdings (BPTH) United States $0.035B 0.00
Aclaris Therapeutics (ACRS) United States $0.033B 0.00
Melinta Therapeutics (MLNT) United States $0.032B 0.00
PharmAthene (ALT) United States $0.032B 0.00
Biomerica (BMRA) United States $0.030B 0.00
ProPhase Labs (PRPH) United States $0.023B 0.00
Opexa Therapeutics (ACER) United States $0.020B 0.00
Heat Biologics (HTBX) United States $0.019B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.018B 1.43
HANCOCK JAFFE (HJLI) United States $0.017B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.015B 0.00
Achieve Life Sciences (ACHV) United States $0.014B 0.00
Cyanotech (CYAN) United States $0.014B 0.00
Onconova Therapeutics (ONTX) United States $0.014B 0.00
Shineco (TYHT) China $0.013B 0.00
Regulus Therapeutics (RGLS) United States $0.012B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.011B 0.00
VAXART, INC (VXRT) United States $0.010B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.009B 0.00
RXi Pharmaceuticals (PHIO) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
Jaguar Animal Health (JAGX) United States $0.006B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.002B 0.00
Xenetic Biosciences (XBIO) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00